Solís GE, Méndez PW, Sánchez FOE, Tolentino LJA, García MMC, Pavón VMÁ

Language: Spanish
References: 18
Page:
PDF size: 216.25 Kb.

ABSTRACT

Background: Cervical cancer remains a major disease, the second leading cause of cancer death of women in our country. Cytology designed more than 70 years has helped to substantially reduce the incidence of this neoplasm.
Objective: To detect a cervical cytology using polyethylene brush, premalignant lesions and invasive that allow send patients the timely diagnosis and treatment.
Methods: We performed a prospective, transversal and observational study which included 1046 patients who were taken a cervical cytology using a polyethylene brush.
Results: The cytology results were reported according to the Bethesda system as negative cancer were 203 (19.4%), inflammatory 792 (75.7%), with report of ASC-US were 9 (0.9%), 1 patient classified AGC (0.1%) as squamous intraepithelial lesions of low-grade (LSIL) reported 31 cases (3.0%) as squamous intraepithelial lesion high-grade (HSIL) identified 3 (0.3%), invasive squamous cell carcinoma was detected one case (0.1 %) and one adenocarcinoma was reported cases (0.1%).
Conclusions. The high quality cytology study, because of the cost, will be remain the only possibility to detect all lesions that precede cancer in all developing countries.

REFERENCES

1. Saslow D, Runowicz CD, Solomon D, et al. AmericanCancer Society guideline for the early detection of cervical neoplasiaand cancer. CA Cancer J Clin 2002;52:342-62.

2. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M,Wilkinson EJ, Solomon D. 2006 consensus guidelines for themanagement of women with abnormal cervical screening tests.J Low Genit Tract Dis 2007;11:201-22.

3. Gustafsson L, Ponten J, Bergstrom R, Adami HO.International incidence rates of invasive cervical cancer beforecytological screening. Int J Cancer 1997;71:159-65.

4. Gustafsson L, Ponten J, Zack M, Adami HO. Internationalincidence rates of invasive cervical cancer after introductionof cytological screening. Cancer Causes Control1997;8:755-63.

5. Parkin DM, Bray F. Chapter 2: The burden of HPVrelatedcancers. Vaccine 2006;24(suppl 3):S3/11-25.

6. Siegel R, Naishadham D, Jemal A. Cancer statistics,2012. CA Cancer J Clin 2012;62:10-29.

7. American Cancer Society. Cancer Facts & Figures2012. Atlanta, GA: American Cancer Society; 2012.

8. Walboomers JM, Jacobs MV, Manos MM, et al.Human papillomavirus is a necessary cause of invasive cervicalcancer worldwide. J Pathol 1999;189:12-9.

9. Chan M. Annual departmental report by the Director of Health. Financial year 1996-97. Hong Kong: Department of Health;1998.

10. Chan SP. Survey of knowledge regarding cervical cytology and current status of screening. HK Pract 1986;8:2204-8.

11. Castle PE, Fetterman B, Cox JT, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer.ObstetGynecol 2010;116:76-84.

12. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J ObstetGynecol 2003;188:1383-92.

13. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34.

14. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.

15. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide 302 HKMJ Vol 5 No 3 September 1999

16. Hutchinson ML, Isenstein LM, Goodman A, et al. Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep processor. Am J Clin Pathol 1994;101:215-9.

17. Chang AR. Experience with a new cervical smear sampling device. HKMJ 1996;2:248-52.

18. Day NE. Effect of cervical cancer screening on Scandinavia. Obstet Gynecol 1984;63:714-8.